Lenalidomide Medical Valley

Lenalidomide, the active ingredient in Lenalidomide Medical Valley, is an immunomodulatory agent (IMiD) presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers, including multiple myeloma, mantle cell lymphoma, and myelodysplastic syndromes, for adult patients with relapsed or refractory disease.

GNH USA supplies Lenalidomide Medical Valley as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support safe distribution.

Lenalidomide is indicated for several hematologic malignancies, targeting abnormal plasma cells and lymphoid proliferation.

- Multiple myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. - Mantle cell lymphoma: contributes to disease control when combined with other agents in adult patients. - Myelodysplastic syndromes: reduces transfusion dependence and modifies disease course in patients with del(5q) cytogenetic abnormality.

Lenalidomide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools that may affect hydration. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Thromboembolic events: increased risk of blood clots. - Severe neutropenia: marked reduction in neutrophil count. - Thrombocytopenia: low platelet levels leading to bleeding risk. - Second primary malignancies: emergence of new cancers in rare cases.

Before initiating therapy, clinicians should evaluate specific risk factors and monitor patients closely.

- Pregnancy risk: avoid use during pregnancy; effective contraception is required. - Thromboembolism risk: assess patient history and consider prophylactic anticoagulation. - Renal impairment: adjust monitoring and dosing in patients with reduced kidney function. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Lenalidomide interacts with several drug classes; careful review of concomitant medications is essential.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Live vaccines: reduced vaccine efficacy and potential infection risk.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may increase lenalidomide plasma levels. - CYP3A4 inhibitors (e.g., ketoconazole): may elevate exposure. - Immunosuppressants (e.g., cyclosporine): may heighten toxicity risk.